Article

Mass. Eye and Ear joins AMD trial

Massachusetts Eye and Ear Infirmary has received institutional review board approval to be a site for Advanced Cell Technology’s phase I/II clinical trial for nonexudative (dry) age-related macular degeneration (AMD), using human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells.

Marlborough, MA-Massachusetts Eye and Ear Infirmary has received institutional review board approval to be a site for Advanced Cell Technology’s phase I/II clinical trial for nonexudative (dry) age-related macular degeneration (AMD), using human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells.

The trial is a prospective, open-label study designed to determine the safety and tolerability of the hESC-derived RPE cells following sub-retinal transplantation into patients with dry AMD. The trial ultimately will enroll 12 patients, with cohorts of three patients each in an ascending dosage format.

“Dry AMD represents one of the largest unmet medical needs in ophthalmology,” said Dean Eliott, MD, a retinal surgeon, scientist, and associate director of the Retina Service at Mass. Eye and Ear. “We appreciate the opportunity to get some first-hand experience with the protocol and be involved with the international team that has been assembled around the U.S. and European trials.”

“We are delighted to announce that Mass. Eye and Ear will participate as a site for our clinical trial for dry AMD,” said Gary Rabin, Advanced Cell Technology’s chairman and chief executive officer. “Dr. Eliott and his team are deeply committed to finding new treatments for preventing blindness, and we very much look forward to tapping into his expertise and insight into the progression of macular degenerative disorders.”

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
© 2025 MJH Life Sciences

All rights reserved.